Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Divestment is part of BASF’s strategic portfolio optimization
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Harnessing advanced data analysis for early detection, prevention and better outcomes
Subscribe To Our Newsletter & Stay Updated
